Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials.
Street D, Jabbari E, Costantini A, Jones PS, Holland N, Rittman T, Jensen MT, Chelban V, Goh YY, Guo T, Heslegrave AJ, Roncaroli F, Klein JC, Ansorge O, Allinson KSJ, Jaunmuktane Z, Revesz T, Warner TT, Lees AJ, Zetterberg H, Russell LL, Bocchetta M, Rohrer JD, Burn DJ, Pavese N, Gerhard A, Kobylecki C, Leigh PN, Church A, Hu MTM, Houlden H, Morris H, Rowe JB.
Street D, et al.
Brain. 2023 Aug 1;146(8):3232-3242. doi: 10.1093/brain/awad105.
Brain. 2023.
PMID: 36975168
Free PMC article.
The advent of clinical trials of disease-modifying agents for neurodegenerative disease highlights the need for evidence-based end point selection. Here we report the longitudinal PROSPECT-M-UK study of progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), mul …
The advent of clinical trials of disease-modifying agents for neurodegenerative disease highlights the need for evidence-based end point sel …